The Impact of Bariatric Surgery on Breast Cancer Recurrence: Case Series and Review of Literature.
Adult
Bariatric Surgery
/ methods
Breast Neoplasms
/ epidemiology
Cohort Studies
Female
Gastrectomy
/ methods
Gastric Bypass
/ methods
Humans
Laparoscopy
/ methods
Middle Aged
Neoplasm Recurrence, Local
/ epidemiology
Obesity, Morbid
/ epidemiology
Prospective Studies
Retrospective Studies
Weight Gain
/ physiology
Weight Loss
/ physiology
Bariatric surgery
Breast cancer
Recurrence
Weight loss
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
pubmed:
31
7
2019
medline:
2
4
2021
entrez:
31
7
2019
Statut:
ppublish
Résumé
Excess body weight has been associated with worsening breast cancer survival. While bariatric surgery has been associated with less incident of breast cancer, the role that bariatric surgery plays after breast cancer diagnosis in terms of both feasibility and in preventing breast cancer recurrence is unclear. We report the outcomes of 13 individuals who underwent bariatric surgery after definitive breast cancer treatment at a single institution. Thirteen females diagnosed with breast cancer (69.2% stage I, 23.1% stage II) at a median age of 42 years received bariatric surgery between 2001 and 2017. The median age of bariatric surgery was 52 years. Of the 13 patients, 46.2% underwent laparoscopic Roux-en-Y gastric bypass and 38.5% laparoscopic sleeve gastrectomy. The median time from breast cancer treatment to bariatric surgery was 3 years. The procedures were well tolerated. One female developed an abdominal wall hematoma. The average weight loss after 1 year and 2 years was 28.1% and 28.2%, respectively. There was a single breast cancer recurrence with a median follow-up of 11.7 years after breast cancer diagnosis and 5.3 years after bariatric surgery. Bariatric surgery after breast cancer treatment is feasible and well tolerated. Prospective trials evaluating bariatric surgery in obese breast cancer survivors should be considered.
Sections du résumé
BACKGROUND
Excess body weight has been associated with worsening breast cancer survival. While bariatric surgery has been associated with less incident of breast cancer, the role that bariatric surgery plays after breast cancer diagnosis in terms of both feasibility and in preventing breast cancer recurrence is unclear.
METHODS
We report the outcomes of 13 individuals who underwent bariatric surgery after definitive breast cancer treatment at a single institution.
RESULTS
Thirteen females diagnosed with breast cancer (69.2% stage I, 23.1% stage II) at a median age of 42 years received bariatric surgery between 2001 and 2017. The median age of bariatric surgery was 52 years. Of the 13 patients, 46.2% underwent laparoscopic Roux-en-Y gastric bypass and 38.5% laparoscopic sleeve gastrectomy. The median time from breast cancer treatment to bariatric surgery was 3 years. The procedures were well tolerated. One female developed an abdominal wall hematoma. The average weight loss after 1 year and 2 years was 28.1% and 28.2%, respectively. There was a single breast cancer recurrence with a median follow-up of 11.7 years after breast cancer diagnosis and 5.3 years after bariatric surgery.
CONCLUSIONS
Bariatric surgery after breast cancer treatment is feasible and well tolerated. Prospective trials evaluating bariatric surgery in obese breast cancer survivors should be considered.
Identifiants
pubmed: 31359344
doi: 10.1007/s11695-019-04099-6
pii: 10.1007/s11695-019-04099-6
pmc: PMC9623809
mid: NIHMS1845047
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
780-785Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK108733
Pays : United States
Organisme : University of Minnesota
ID : University of Minnesota Innovation Research Grant
Références
Breast Cancer Res Treat. 2010 Oct;123(3):627-35
pubmed: 20571870
Ann Surg. 2019 Jan;269(1):95-101
pubmed: 28938270
J Clin Oncol. 2016 Mar 20;34(9):927-35
pubmed: 26786933
N Engl J Med. 2007 Aug 23;357(8):741-52
pubmed: 17715408
N Engl J Med. 2010 Dec 2;363(23):2211-9
pubmed: 21121834
JAMA. 2018 Jan 16;319(3):266-278
pubmed: 29340678
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
J Clin Oncol. 2014 Jul 20;32(21):2231-9
pubmed: 24934783
JAMA. 2018 Jun 19;319(23):2442
pubmed: 29922821
Ann Oncol. 2014 Oct;25(10):1901-14
pubmed: 24769692